Bayer seeks expanded EU Eylea label

Bayer AG (Xetra:BAYN) submitted an MAA to EMA to expand the label for Eylea aflibercept to include treatment of macular edema following central retinal vein occlusion (CRVO). Last month, the European Commission approved the product to treat wet age-related macular degeneration (AMD). Eylea is approved for both indications in the U.S. ...